Physician profile
Israa Ali
NPI 1841687720
$4,755.26
in general payments reported to CMS, 2019-2025
30 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.61 · 2021: $150 · 2022: $355 · 2023: $1,058 · 2024: $1,431 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,225 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.43 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $656.42 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $512.44 | 2022-2025 | Ozempic, Sogroya, Rybelsus |
| Corcept Therapeutics | $494.67 | 2021-2025 | Korlym |
| Amgen INC. | $445.98 | 2022-2025 | Evenity, Prolia, Tepezza |
| Neurocrine Biosciences, INC. | $385.95 | 2025 | |
| Dexcom, INC. | $365.19 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $338.87 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.18 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $161.50 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.34 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Madrigal Pharmaceuticals | $131.10 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $130.28 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $119.01 | 2025 | Yorvipath |
| Cequr Corporation | $109.44 | 2024-2025 | Cequr Simplicity |
| Opko Pharmaceuticals, LLC | $48.74 | 2024 | Rayaldee |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $45.47 | 2025 | |
| Abbvie INC. | $41.32 | 2024-2025 | |
| Amryt Pharma Holdings LTD | $36.82 | 2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $36.72 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $34.95 | 2023 | Tlando, Nocdurna, Xyosted |
| Insulet Corporation | $34.90 | 2025 | Omnipod |
| Halozyme INC | $32.67 | 2023 | |
| Mannkind Corporation | $29.42 | 2023-2025 | Afrezza |
| Astellas Pharma US INC | $28.58 | 2024 | Veozah |
| Recordati_rare_diseases_inc. | $23.11 | 2023 | Isturisa |
| Abbott Laboratories | $21.87 | 2025 | Freestyle Libre 3 |
| Embecta Corp. | $18.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $18.37 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2023 | Farxiga |
| W. L. Gore & Associates, INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Israa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.